MGCD0103, a selective histone deacetylase inhibitor, coameliorates oligomeric Aβ 25-35 -induced anxiety and cognitive deficits in a mouse model

Hei Jen Huang, Hsin Yu Huang, Hsiu Mei Hsieh-Li*


研究成果: 雜誌貢獻期刊論文同行評審

8 引文 斯高帕斯(Scopus)


Aims: Recently, histone deacetylase (HDAC) inhibitors are considered a possible therapeutic strategy in Alzheimer's disease (AD). However, HDACi treatments exhibit diverse functions with unfavorable effects in AD. Thus, the development of selective HDACi without side effects is urgently needed. Methods: HDACi, namely, BML210, MGCD0103, PXD101, and Droxinostat, were screened in mouse hippocampal primary cultures incubated with oligomeric Aβ 25-35 (50 μmol/L). MGCD0103 was chosen for in vivo tests and was intraperitoneally injected into C57BL/6J mice (0.5 mg/kg, once per day) for 4 weeks following an intrahippocampal CA1 injection of oligomeric Aβ 25-35 . Brain samples were collected for pathological analyses after the behavioral analyses including open- field test (OFT), elevated plus maze (EPM), Y-maze, and Morris water maze (MWM). Results: Among the HDACi, MGCD0103 exhibited significant neuroprotection against the Aβ toxicity in primary cultures. MGCD0103 coattenuated cognitive deficits and anxiety against Aβ damage in mice. MGCD0103 further ameliorated pathological features such as the levels of acetylated histone 3 at Lys 9 site (H3K9) and α-tubulin, synaptophysin, Aβ, tau protein phosphorylation, and serotonergic neuron loss against Aβ toxicity. Furthermore, chronic MGCD0103 treatment did not show liver or kidney toxicity in mice. Conclusions: These results reveal MGCD0103 could be a potential therapeutic agent against AD.

頁(從 - 到)175-186
期刊CNS Neuroscience and Therapeutics
出版狀態已發佈 - 2019 二月 1

ASJC Scopus subject areas

  • 藥理
  • 精神病學和心理健康
  • 生理學(醫學)
  • 藥學(醫學)


深入研究「MGCD0103, a selective histone deacetylase inhibitor, coameliorates oligomeric Aβ <sub>25-35</sub> -induced anxiety and cognitive deficits in a mouse model」主題。共同形成了獨特的指紋。